Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California. Lloyds forecast: will Lloyds share price return to £1? Third party data forecastWhat’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
13:36, 8 July 2024
Infosys shareholders: Who owns the most INFY stock?Who are the major shareholders and decision-makers of Infosys?
07:12, 29 April 2024
Tesla shareholders: Who owns the most TSLA stock?In this guide to Tesla’s ownership structure, we look at the biggest TSLA shareholders – both institutional and individual
08:00, 19 April 2024
US Earnings Week Ahead: Walt Disney, Uber, and Pepsi CoThe last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.
14:43, 2 February 2024